Emgality
Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population
August 6, 2019Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma
New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …
Eli Lilly’s Emgality approved in the US for episodic cluster headache
June 5, 2019Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma
Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
May 8, 2019Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …
Eli Lilly’s Emgality cleared for treatment of migraine in Europe
November 20, 2018Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma
Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
